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Abstract 46 
BK polyomavirus (BKPyV) is a small DNA virus that establishes a life-long persistent infection in 47 
the urinary tract of most people. BKPyV is known to cause severe morbidity in renal transplant 48 
recipients and can lead to graft rejection. The simple 5.2 kilobase pair dsDNA genome expresses 49 
just seven known proteins, thus it relies heavily on host machinery to replicate. How the host 50 
proteome changes over the course of infection is key to understanding this host:virus interplay. 51 
Here for the first time quantitative temporal viromics has been used to quantify global changes in 52 
>9,000 host proteins in two types of primary human epithelial cell throughout 72 hours of BKPyV 53 
infection. These data demonstrate the importance of cell cycle progression and pseudo-G2 arrest in 54 
effective BKPyV replication, along with a surprising lack of innate immune response throughout 55 
the whole virus replication cycle. BKPyV thus evades pathogen recognition to prevent activation 56 
of innate immune responses in a sophisticated manner.  57 
 58 
Importance 59 
BK polyomavirus can cause serious problems in immune-suppressed patients, in particular kidney 60 
transplant recipients who can develop polyomavirus-associated kidney disease. In this work, we 61 
have used advanced proteomics techniques to determine the changes to protein expression caused 62 
by infection of two independent primary cell types of the human urinary tract (kidney and bladder) 63 
throughout the replication cycle of this virus. Our findings have uncovered new details of a 64 
specific form of cell cycle arrest caused by this virus and importantly we have identified that this 65 
virus has a remarkable ability to evade detection by host cell defence systems. In addition, our data 66 
provide an important resource for the future study of kidney epithelial cells and their infection by 67 
urinary tract pathogens.  68 
 3 
Introduction 69 
BK Polyomavirus (BKPyV) is a small, non-enveloped, double stranded DNA virus that was first 70 
identified in 1971 (1). As a ubiquitous pathogen, it establishes a life-long persistent infection in the 71 
kidneys of most humans (2). While infection with BKPyV is subclinical in the vast majority of 72 
individuals, it is a significant cause of morbidity in the immunosuppressed, in particular kidney 73 
and haematopoietic stem cell transplants (HSCT) recipients. Polyomavirus associated nephropathy 74 
(PVAN) affects ~8% of kidney transplant patients, however treatment is currently limited to a 75 
reduction in immune suppression. Only a small number of anti-BKPyV drugs are available, all 76 
exhibiting significant nephrotoxicity, leading to graft decline of function and loss in ~85% of 77 
PVAN sufferers (3). In up to 15% of HSCT patients, BKPyV leads to haemorrhagic cystitis (HC) 78 
and severely reduced rates of HSCT recovery (4). 79 
As with all polyomaviruses, BKPyV is structurally simple. The dsDNA genome is ~5.2 kilobase 80 
pairs long and encodes seven proteins, three of which form the virus capsid (VP1, VP2 and VP3). 81 
The four non-structural proteins (large T antigen (LTAg), small T antigen (stAg), truncTAg and 82 
agnoprotein) have numerous functions and interact with multiple host factors. For example, LTAg 83 
binds members of the Retinoblastoma protein family, inhibiting their regulation of the G1/S phase 84 
checkpoint of the cell cycle. As a result, viral infection stimulates cell cycle progression into S 85 
phase, facilitating viral DNA genome replication (5, 6). LTAg also binds p53, altering the 86 
regulation of both apoptosis and cell cycle progression (7). stAg modulates the phosphorylation of 87 
>300 cell cycle proteins and LTAg, through interaction with protein phosphatase 2A (8, 9). The 88 
role of agnoprotein is less well understood, although a wide range of activities have been proposed 89 
including action as a viroporin, enhancing viral DNA replication through interaction with the 90 
processivity factor proliferating cell nuclear antigen (PCNA), and enhancing egress of virions from 91 
the nucleus (10, 11). 92 
The limited coding capacity of BKPyV necessitates co-option of multiple host factors in order to 93 
replicate and persist. Previous studies investigating how BKPyV infection modulates the host cell 94 
environment have primarily been conducted at the level of the transcriptome, which may not be 95 
reflected in the proteome. Infection in primary Renal Proximal Tubule Epithelial (RPTE) and 96 
Human Umbilical Vein Endothelial (HUV-EC) cells has been studied, either using microarray (12, 97 
13) or RNAseq (14, 15). Such analyses do not provide information about virus-induced changes to 98 
cellular proteins. To date there has only been one limited analysis of changes to the host cell 99 
proteome in BKPyV infection, where stable isotope labelling with amino acids in cell culture 100 
(SILAC) was used to quantify protein changes in nuclei isolated from primary RPTE cells at 3 101 
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days post infection. In this study ~2000 proteins were quantified, and the effect of infection on 102 
proteins outside the nucleus could not be assessed (16). 103 
To gain a comprehensive global understanding of changes in host and viral proteins throughout the 104 
whole course of BKPyV infection, we conducted a 10-plex quantitative temporal viromic analysis 105 
(QTV) of two independent BKPyV-permissive primary human cell types, RPTE and human 106 
urothelial (HU) cells. QTV uses tandem mass tags (TMT) and MS3 mass spectrometry to quantify 107 
the relative abundance of proteins throughout the whole time course of infection (17). These data 108 
have provide the broadest global analysis of proteome changes caused by BKPyV infection, which 109 
has provided additional details of a specialised form of cell cycle arrest that is induced by this 110 
virus in primary cells. In addition, we have uncovered a complete lack of induction of innate 111 
immune responses at the protein level in BKPyV infected cells suggesting that this virus has 112 
evolved a sophisticated mechanism for evading pathogen recognition. 113 
 114 
Results 115 
Quantitative Temporal Viromic analysis of BKPyV infection 116 
To build a global picture of changes in host and viral proteins throughout the course of BKPyV 117 
infection, we infected primary renal (RPTE) and bladder (HU) epithelial cells with BKPyV 118 
Dunlop strain. We first used 10-plex TMT and MS3 mass spectrometry to quantify changes in 119 
protein expression over three key time points of infection spanning the single-step replication 120 
cycle of this virus (0-72 hours) (Experiment 1; Fig. 1A). Cells were infected at a multiplicity of 121 
infection (MOI) of 5 infectious units per cell ensuring greater than 90% infection in both RPTE 122 
and HU cells (data not shown). In this experiment a total of 8985 cellular and 5/7 viral proteins 123 
were quantified in both cell types, providing a global view of changes in protein expression during 124 
infection in primary human epithelial cells from the kidney and bladder. Data from all proteomic 125 
experiments in this study are shown in Table S1. Here, the worksheet ‘‘Plots’’ is interactive, 126 
enabling generation of graphs of protein expression of any of the human and viral proteins 127 
quantified. 128 
In uninfected cells, RPTE and HU cells exhibit differential expression of proteins, as expected 129 
from two different cell types. In infected cells, few changes occurred by 24 h of infection, however 130 
more substantial differences were seen by 48 and 72 h (Fig. 1B and C). In RPTE cells 191 cellular 131 
proteins increased >2-fold, while 149 proteins decreased >2-fold at any time point during BKPyV 132 
infection. In HU cells 130 proteins increased >2-fold and 55 decreased >2-fold. Many proteins 133 
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showed similar changes in both cell types, although cell type-specific effects were also seen (Fig. 134 
1D; R=0.61). We reasoned that those protein changes which were important for viral replication 135 
would be common to different cell types. By combining the two datasets, we found that just 86 136 
cellular proteins, less than 1% of all proteins quantified, were upregulated >2-fold in both RPTE 137 
and HU cells (Fig. 1D). 138 
The lack of change in the host cell proteome at the earliest time point of 24 hpi suggested little or 139 
no effect of virus binding and penetration. To investigate this further a second TMT-based whole 140 
cell proteomics experiment (Experiment 2) was conducted repeating 24 and 48 hpi time points 141 
with an additional earlier 12 hpi time point, where RPTE cells were infected with UV-inactivated 142 
or unmodified BKPyV at MOI 5 (Fig. 2, Table S1). In Experiment 2 a total of 7698 cellular 143 
proteins were quantified, some of which were not detected in Experiment 1, giving a combined 144 
total of 9304 cellular proteins quantified across both experiments. Very few changes in protein 145 
abundance were observed at 12 or 24 hpi during infection with unmodified BKPyV, while at 48 146 
hpi cellular proteins upregulated were similar to those observed in the first experiment at the same 147 
time point (Fig. 2B-D). UV-inactivated virus induced virtually no changes at any time point, 148 
suggesting that virus replication is necessary to cause the observed changes in host protein 149 
abundance (Fig. 2B). 150 
Temporal Analysis of BK Polyomavirus Protein Expression 151 
Expression of the early BKPyV proteins, LTAg and stAg, was observed from 24 hpi, closely 152 
followed by late proteins, agnoprotein, VP1 and VP2. Profiles from HU and RPTE cells (both 153 
experiments) corresponded well (Fig. 1E and 2E). We were unable to assign peptides to VP3 due 154 
to its 100% sequence identity with the C terminus of VP2, and the single unique peptide 155 
corresponding to the extreme N-terminus of VP3 was not quantified. Likewise, TruncTAg was not 156 
identified due to its similarity to full length LTAg: the only difference in protein sequence are the 157 
C-terminal 3 amino acids of TruncTAg, which directly follow a cluster of lysine and arginine 158 
residues and so would not be expected to be identified by our mass spectrometry analysis. 159 
BKPyV does not cause induction of innate immune responses in infected RPTE cells 160 
One surprising observation from our QTV analyses was an apparent lack of an innate immune 161 
response to BKPyV infection. Of the 131 quantified proteins with annotated innate immune 162 
functions or the 69 quantified proteins with annotated antiviral functions only five were up- or 163 
downregulated >2-fold, and these changes were not consistent between the two independent cell 164 
types or experiments (Fig. 3A and Table S2). Despite RPTE cells being capable of mounting a 165 
response to type I interferon, the expression of interferon stimulated genes MX1, ISG15, IFIT1, 166 
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IFIT2, IFIT3, IRF3, IFI16, and BST2 remained unchanged upon BKPyV infection throughout the 167 
time course, as assessed both by proteomics and Western blot (Fig. 3B and C). This was 168 
unexpected given that by 72 hpi large amounts of viral DNA and proteins as well as progeny 169 
virions were present within cells. This lack of response suggests BKPyV has evolved a highly 170 
effective immune-evasion activity, which could be due to either viral DNA and proteins not being 171 
recognised by host pathogen recognition receptors (PRRs) in these primary epithelial cells, or 172 
suppression of PRR signalling pathways during BKPyV infection. 173 
Activation of RNA and DNA sensors invariably leads to IRF3 phosphorylation and translocation 174 
into the nucleus, leading to transcription of type I and III interferons. We analysed whether RPTE 175 
cells have functional RNA and DNA sensing pathways, and whether these were activated in 176 
response to BKPyV infection. The phosphorylation and localisation of IRF3 was investigated by 177 
Western blot and immunofluorescence microscopy following BKPyV infection or treatment with 178 
Poly I:C or stimulatory DNA. Poly I:C or stimulatory DNA caused clear nuclear translocation of 179 
IRF3 in RPTE cells, with poly I:C having the greatest effect (Fig. 4A). However, BKPyV-infected 180 
RPTE cells had no detectable change in IRF3 localisation and appeared no different to mock 181 
infected cells apart from characteristic enlarged nuclei in virus infected cells (Fig. 4A). 182 
Furthermore, Western blot analysis showed no stimulation of IRF3 phosphorylation in BKPyV-183 
infected RPTE cells, whereas both poly I:C and stimulatory DNA transfection caused robust IRF3 184 
phosphorylation (Fig. 4B). These results suggest that signal transduction pathways that would 185 
usually lead to activation of IRF3-specific kinases are not activated in infected cells either due to 186 
an inability to sense BKPyV nucleic acids or due to active inhibition by BKPyV. 187 
To investigate whether the lack of viral sensing is due to evasion of nucleic acid detection or active 188 
suppression of IRF3 phosphorylation, RPTE cells were mock or BKPyV-infected and 189 
subsequently stimulated with Poly I:C or stimulatory DNA at 42 hpi, prior to analysis at 48 hpi. 190 
Nuclear translocation and robust phosphorylation of IRF3 was observed in response to both RNA 191 
and DNA, irrespective of whether the cells were infected with BKPyV or mock-infected (Fig. 5A 192 
and B). This suggests that BKPyV does not actively inhibit nucleic acid sensing pathways, IRF3 193 
phosphorylation or IRF3 nuclear translocation. As BKPyV does not inhibit downstream activation 194 
of RNA or DNA sensing pathways this suggests BKPyV evades nucleic acid and other pathogen 195 
associated molecular pattern (PAMP) sensing pathways altogether, despite high concentrations of 196 
viral DNA, RNA and protein within these primary renal epithelial cells. 197 
Cell cycle associated proteins are the primary target of BKPyV 198 
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To investigate host cell functions that were modified by BKPyV, the Database for Annotation, 199 
Visualisation and Integrate Discovery (DAVID) was used to identify pathways enriched among 200 
proteins up- or downregulated during BKPyV infection (18). Amongst upregulated proteins, 201 
similar terms were enriched between HU and RPTE cells (both from experiments 1 and 2). ‘Cell 202 
cycle’ and terms related to the cell cycle dominated this analysis (Fig. 6A, Tables S3 and S4). 203 
Terms associated with the G2/M phase of the cell cycle were particularly enriched, including: 204 
chromosome, microtubule, spindle, sister chromatid cohesion and DNA damage. G2/M phase 205 
arrest has previously been observed in a number of different polyomavirus infections (19-22).  206 
Cellular proteins associated with G2/M phase of the cell cycle generally increased in abundance 207 
throughout BKPyV infection including: M-phase (CDCA3), spindle formation (CDC20, CDCA2), 208 
kinetochore assembly, sister chromatid segregation and cytokinesis (KIF11, CENPK, SKA1, 209 
KIF22, ANLN), DNA repair and control of re-replication (HELLS, GMNN) and G2/M-associated 210 
cyclins and cyclin-dependent kinases (CDK1, cyclin A2 and cyclin B1) (Fig. 6B). Proteins 211 
associated with the G1 phase, such as cyclin D2, were observed to decrease in abundance. As 212 
expected, levels of the tumour suppressor p53 were elevated during BKPyV infection; 213 
polyomavirus LTAg binds, stabilises and inactivates p53 (5, 23, 24). Interestingly, MDM2, the 214 
ubiquitin ligase that normally mediates p53 degradation, was depleted during BKPyV infection 215 
(Fig. 6B).  216 
We confirmed these results for a number of cell cycle regulatory proteins by Western blot 217 
throughout the time course of BKPyV infection in both RPTE and HU cells (Fig. 6C). 218 
Immunofluorescence microscopy of BKPyV or mock-infected RPTE cells further confirmed the 219 
increase in cyclin B1 and CDK1 during BKPyV infection, and furthermore that cyclin B1 220 
remained cytoplasmic during BKPyV infection (data not shown). This suggests that infected cells 221 
do not proceed into M phase, when cyclin B1 would normally relocalise to the nucleus (25).  222 
MDM2 and p53 levels are modulated by LTAg and cell cycle arrest 223 
BKPyV-induced upregulation of p53 and downregulation of MDM2 was also confirmed by 224 
immunofluorescence (Fig. 7). The E3 ubiquitin ligase MDM2 is a negative regulator of both p53 225 
and itself, leading to ubiquitinylation and degradation of p53 and MDM2 (26). In addition, p53 is a 226 
transcription factor for both itself and MDM2 (27), whose transcriptional activity is governed by 227 
the strength of extracellular and intracellular signals, such as cell cycle checkpoints, leading to the 228 
establishment of both positive and negative feedback loops (28). 229 
Polyomavirus LTAgs are well established to efficiently bind, stabilise and inhibit p53 (5, 23, 24), 230 
leading to increased p53 levels in BKPyV infected cells. Our data now demonstrates that this is 231 
 8 
accompanied by a decrease in MDM2 levels. Interplay between BKPyV infection, MDM2 and p53 232 
was investigated using the MDM2 inhibitor Nutlin-3. Nutlin-3 occupies the p53 binding pocket on 233 
MDM2 obstructing their interaction and leading to reduced p53 ubiquitinylation. In addition, 234 
Nutlin-3 leads to increased transcription of MDM2 due to the release of active p53 (29). Mock or 235 
BKPyV infected RPTE cells were treated with Nutlin-3 at 2 hpi, or DMSO as a control, and fixed 236 
at 48 hpi. Cells were immunostained for expression of MDM2, p53, and LTAg (infection marker) 237 
(Fig. 7A). Low endogenous levels of both MDM2 and p53 were observed in the nuclei of 238 
untreated mock infected cells. BKPyV infection lead to a reduction in MDM2, while p53 239 
increased, correlating with the changes observed in the proteomics data. Mock infected cells 240 
treated with Nutin-3 showed increased levels of MDM2, accompanied by a slight increase in p53 241 
levels, in accordance with published effects of Nutlin-3 (29). Interestingly, MDM2 levels did not 242 
increase in BKPyV infected cells treated with Nutlin-3 and in fact MDM2 levels were observed to 243 
reduce, whilst p53 levels were once again increased. This suggests that during infection MDM2 244 
remains able to self-ubiquitinylate, leading to its degradation in the presence of Nutlin-3, however 245 
transcription of MDM2 by p53 is apparently inhibited, likely due to p53 sequestration by LTAg.  246 
To investigate whether LTAg expression alone was sufficient to cause the observed MDM2 247 
decrease and p53 increase RPTE cells were transfected with a LTAg expression plasmid. At 2 h 248 
cells were treated with Nutlin-3 or DMSO and then in addition some samples were treated at 24 h 249 
with a CDK1-specific inhibitor, RO-3306, to simulate BKPyV induced cell cycle arrest. Cells 250 
were fixed at 48 h and immunostained for MDM2, p53, and LTAg (Fig. 7B). Expression of LTAg 251 
alone was sufficient to reduce MDM2 levels, however p53 levels were increased only slightly 252 
suggesting other effects of BKPyV infection in addition to LTAg expression modulate p53 and 253 
MDM2 levels. Nutlin-3 treatment did not alter the effects of LTAg on MDM2 or p53 levels. 254 
Treatment of LTAg expressing cells with the CDK1 inhibitor RO-3306 lead to a marked increase 255 
in p53 expression, while MDM2 levels were once again decreased. Combined Nutlin-3 and RO-256 
3306 treatment further enhanced the increase of p53 in LTAg expressing cells. Taken together, 257 
these data suggest LTAg binding to p53 displaces MDM2 leading to p53 stabilisation and MDM2 258 
degradation, but LTAg binding also prevents p53-dependent expression of MDM2 and p53. 259 
Furthermore, virus infection or G2/M arrest stimulates p53 expression, possibly via a DNA 260 
damage-type response. 261 
BKPyV induced G2/M phase arrest is prevented by inhibition of CDK1 & CDK2, but not by 262 
inhibition of CDK1 alone or CDK4 & CDK6 263 
Given the dysregulation of cell cycle-related proteins during BKPyV replication, we postulated 264 
that a virus-induced pseudo-G2 phase may serve a number of roles in BKPyV replication. We 265 
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therefore investigated the effect of BKPyV infection on the host cell cycle status in the presence or 266 
absence of various CDK inhibitors. Polyomavirus replication is heavily reliant on the host DNA 267 
synthesis machinery and it has previously been shown that either BKPyV infection or JCPyV 268 
LTAg expression alone can cause cells to arrest in the G2/M phase of the cell cycle (22, 30, 31). 269 
However, the impact of CDK inhibitors on BKPyV-induced arrest has not been fully investigated. 270 
RPTE cells were infected with BKPyV, treated with CDK inhibitors after 24 hpi to allow 271 
sufficient time for virus entry and initiation of early gene expression, then subsequently harvested 272 
at 48 hpi and analysed by flow cytometry to compare cell cycle profiles. PD0332991 was used to 273 
inhibit CDK4 and 6, which are active in G1 phase, Roscovitine was used to inhibit CDK1 and 2, 274 
which are active throughout S, G2, and M phase, and RO-3306 was used to inhibit CDK1, which 275 
is active in G2 and M phase. In mock-infected RPTE cells, all three inhibitors produced the 276 
expected effects: PD0332991 increased the proportion of cells in G1 from 72% to 84% (p<0.05), 277 
Roscovitine showed little change in proportion of cells in any cell cycle phase because of its broad 278 
effect on S, G2 and M phases, and RO-3306 showed an increased proportion of cells in G2/M 279 
(18% to 23%) and reduced proportion in G1 (72% to 65%), although this did not reach statistical 280 
significance (Fig. 8A and B). Cell viability remained above 90% for all inhibitor conditions used 281 
(Fig. 8C). Infection of RPTE cells with BKPyV in the absence of any inhibitor significantly 282 
increased the proportion of cells in G2/M from 18% to 31% and decreased the proportion of cells 283 
in G1 (72 % to 56%; p<0.01), consistent with BKPyV-induced G2 arrest observed in previous 284 
published data (30). BKPyV-infected cells that were treated with PD0332991 showed a significant 285 
decrease in the proportion of cells in G1 compared to uninfected cells treated with PD0332991 286 
(84% to 58%; p<0.001). While a slight increase was observed in the proportion of cells in G1 for 287 
BKPyV infected and PD0332991 treated cells compared to control BKPyV infected cells (56% to 288 
58%) this did not reach statistical significance. This suggests that inhibition of CDK4 and 6 does 289 
not prevent BKPyV driving infected cells through the G1/S checkpoint (due to Rb inactivation by 290 
LTAg) or arresting cells in G2/M. In contrast, treatment of infected cells with Roscovitine, which 291 
inhibits both CDK1 and 2, appears to severely restrict BKPyV-stimulated S phase entry and G2/M 292 
arrest, as the cell cycle status was similar to that of mock-infected cells with no significant change 293 
in the proportion of cells in any cell cycle phase. BKPyV infected cells treated with RO-3306 294 
(CDK1 inhibitor) showed a similar cell cycle profile to that of control BKPyV infected cells, with 295 
no significant difference in the proportion of cells in any cell cycle phase (Fig. 8A). Comparison of 296 
mock infected RO-3306 treated cells with BKPyV infected RO-3306 treated cells showed 297 
increased proportion of cells in G2/M and S with a corresponding decrease in G1 (65% to 49%; 298 
p<0.05). This suggests that BKPyV infection and CDK1 inhibition have a similar and additive 299 
effect on the cell cycle, namely induction of G2/M arrest. 300 
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Inhibition of CDK1 and CDK2 or CDK1 alone reduces BKPyV replication 301 
The ability of BKPyV to induce a pseudo-G2 arrest in the presence of CDK1 or CDK4/6 inhibition 302 
suggested that virus replication should be unaffected in such conditions, while inhibition of 303 
CDK1/2 should perturb viral replication due to inhibition of S phase progression. To investigate if 304 
this was the case we next analysed the effect of CDK inhibitors on viral genome synthesis in 305 
BKPyV infected RPTE cells. Infected cells were treated with each inhibitor at 24 hpi and 306 
harvested at 48 hpi. Viral and host cell DNA was quantified using qPCR to determine viral DNA 307 
copy numbers per cell and were normalised to uninhibited controls (arbitrarily set to 1). Inhibition 308 
of CDK4/6 had no significant effect on viral genome synthesis, while inhibition of CDK1 and 2 by 309 
Roscovitine showed a 7.4-fold reduction in the synthesis of BKPyV genome, likely due to the 310 
restriction of cells from entering and progressing through S phase (Fig. 9A). Surprisingly, 311 
inhibition of CDK1 alone by RO-3306 also caused a significant, although more modest, 2.3-fold 312 
reduction in BKPyV genome synthesis. This suggests that, despite this inhibitor having little effect 313 
on BKPyV-driven cell cycle progression, CDK1 activity is important for efficient viral genome 314 
synthesis. 315 
The effects of these CDK inhibitors on viral protein synthesis was similarly investigated (Fig. 9B). 316 
Inhibition of CDK4 and 6 had no observable effect on viral protein synthesis, while inhibition of 317 
CDK1 and 2 by Roscovitine substantially reduced viral protein expression levels. Inhibition of 318 
CDK1 alone by RO-3306 showed only small reductions in viral protein levels. 319 
Analysis of infectious virus production in the presence or absence of these CDK inhibitors also 320 
demonstrated a similar trend. Inhibition of CDK4 and 6 caused only a slight reduction of 321 
infectious titres, whereas inhibition of CDK1 and 2 by Roscovitine resulted in a significant 80-fold 322 
reduction of virus production, unsurprisingly given the inhibition of viral DNA and protein 323 
synthesis (Fig. 9C). Inhibition of CDK1 alone by RO-3306 caused a significant reduction of 324 
infectious virus titre by >3-fold. These data further suggest that CDK1 activity is important for the 325 
efficient production of infectious viruses. 326 
 327 
Discussion 328 
By employing the power and sensitivity of TMT-based MS3 mass spectrometry technology, we 329 
have been able to uncover BKPyV-induced changes to protein abundance and a global view of 330 
protein expression within these human cell types. Importantly, these studies were conducted in 331 
primary human cells from epithelial tissue representing the natural sites of replication in vivo. 332 
 11 
Therefore, this work also provides a comprehensive proteomic resource for future studies on 333 
human renourinary epithelial biology. 334 
One of the most surprising findings of this study was just how few of the ~9000 cellular proteins 335 
that were quantified changed in abundance in response to BKPyV infection. In fact, just 235 were 336 
found to be upregulated and 196 downregulated >2-fold or more across either cell type at any time 337 
point, which corresponds to <5% of the total proteome. Previous studies that applied a similar 338 
TMT-based approach to infection with human cytomegalovirus (HCMV), another dsDNA virus, 339 
revealed that 56% of cellular proteins changed in abundance more than 2-fold during the course of 340 
infection (17). This suggests that BKPyV, and presumably other polyomaviruses, are so highly 341 
adapted to their host that they only need to induce subtle changes to host gene expression to 342 
reprogram cells into virus-producing factories. This also suggests polyomaviruses can very 343 
effectively evade detection by host pathogen recognition receptors despite producing high 344 
concentrations of foreign (viral) nucleic acid and proteins during productive infection. 345 
For host proteins induced by BKPyV infection, we identified substantial overlap between the two 346 
primary cell types, with many of the same or highly related functional clusters identified by 347 
DAVID analysis. This includes clusters such as ‘DNA damage’ and the ‘Fanconi Anaemia’ 348 
pathway, which have been previously described as important during polyomavirus replication to 349 
ensure viral genome replication maintains high fidelity (30). Interestingly, the majority of the 350 
functional clusters identified as upregulated in BKPyV infection are related to cell cycle activity 351 
and regulation, in particular activities associated with G2 and M phases. In fact, BKPyV infection 352 
appears to have a similar ‘G2/M arrest’ effect on cell cycle status as the CDK1-specific inhibitor 353 
RO-3306, a drug commonly used to arrest cells in G2. The fact that infected cells do not progress 354 
into authentic mitosis is supported by the observation that cyclin B1 remains predominantly 355 
cytoplasmic despite higher protein levels in infected cells, and supports previously published data 356 
indicating G2/M phase arrest is driven by polyomavirus infection (5-7, 22, 32). Our data now 357 
provides a greater understanding of host protein profiles that are associated with polyomavirus-358 
induced G2 arrest, and it would be interesting to compare these observations to the effects of RO-359 
3306 or other specific CDK1 inhibitors on cellular protein expression profiles. 360 
Our data also indicate a specific perturbation of the p53-MDM2 axis by BKPyV infection, where 361 
MDM2 is reduced and p53 is increased but kept inactive by LTAg binding. However, these 362 
changes require more than just LTAg expression, and are also driven by additional effects of 363 
BKPyV infection related to G2/M arrest and potentially DNA damage responses. Our findings 364 
suggest the following model: low MDM2 and p53 levels are maintained in uninfected cells due to 365 
their poly-ubiquitinylation by MDM2 and subsequent proteosomal degradation (Fig. 10A). 366 
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Inhibition of MDM2-p53 interaction by Nutlin-3 releases p53 which then stimulates MDM2 367 
expression (Fig. 10B). Interaction of LTAg with p53 displaces MDM2, thereby causing MDM2 to 368 
be destroyed by the proteasome, and so protects p53 from degradation but inhibits p53 369 
transcriptional activity prevent induction of de novo MDM2 expression (Fig. 10C). Therefore, the 370 
expression of just LTAg results in decreased MDM2 levels but only a modest increase in p53. 371 
During active BKPyV infection, p53 expression is induced by some other effect(s) of virus 372 
replication, and these additional copies of p53 are also bound and inactivated by LTAg (Fig. 10D). 373 
We predict that stimulation of p53 expression during BKPyV infection is via a DNA damage 374 
response pathway, which can be mimicked by inducing a G2 arrest through inhibition of CDK1. 375 
Polyomaviruses have a well-established capacity to drive cells into S-phase by overriding the G1/S 376 
checkpoint via the activity of LTAg. It is therefore unsurprising that inhibition of CDK4 and 6 has 377 
little-to-no effect on the ability of BKPyV to drive cell cycle progression or to replicate. CDK4 378 
and 6, in complex with cyclin D, are normally responsible for phosphorylation of Rb and release 379 
of E2F proteins allowing passage through the G1/S checkpoint (33). This is bypassed through the 380 
binding of LTAg to Rb family proteins, releasing E2F proteins enabling S-phase entry that is 381 
unconstrained by upstream factors (5, 6). 382 
In contrast Roscovitine, a potent inhibitor of CDK1 and 2, caused a global cell cycle arrest, 383 
irrespective of BKPyV infection, and reduced BKPyV replication. Similar effects of Roscovitine 384 
on polyomavirus replication have been previously been attributed to inhibition of CDK1 activity 385 
alone (34). However, our data suggests the effect of Roscovitine are more likely due to inhibition 386 
of CDK2 activity, or the combination of inhibiting both CDK1 and 2. Inhibition of both these 387 
cyclin dependent kinases causes a rather global block to cell cycle progression; CDK2 is active in 388 
both late G1 and S phase, while CDK1 is active in G2 and M phase (35). CDK2 activity is 389 
required immediately after G1 checkpoint clearance and beyond, and so the primary cause of 390 
BKPyV inhibition by Roscovitine could be due to a failure to activate S-phase proteins required 391 
for viral genome synthesis and consequent protein expression. Interestingly, we also observed 392 
reduced expression of LTAg in Roscovitine treated cells. This might be attributed to inhibited 393 
progression through S phase, thus leading to reduced viral genome copy numbers from which 394 
LTAg is transcribed, although other effects of Roscovitine that inhibit transcription, such as 395 
inhibition of CDK7 and 9, may also contribute to this effect (36) 396 
Somewhat more intriguing is the effect of CDK1-specific inhibition on BKPyV infection; RO-397 
3306 caused significant reductions in viral DNA synthesis and infectious virus assembly. This was 398 
surprising because CDK1 activity is normally important for the transition through G2 and into M-399 
phase, and so inhibition of CDK1 would not be expected to inhibit progression through S-phase 400 
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and thus viral DNA replication. Whether CDK1 activity is required directly or indirectly to 401 
enhance DNA synthesis or other S-phase activities required for BKPyV genome replication, or the 402 
process of virion assembly, remains to be determined. 403 
Moreover, our data have demonstrated that BKPyV infection of renourinary epithelial cells does 404 
not appear to cause the induction of antiviral responses in agreement with published data of RPTE 405 
cells (12, 14, 15). Both RPTE and HU cells express the appropriate receptors, signalling pathways 406 
and transcription factors associated with sensing and responding to DNA viruses, such as cGAS 407 
(MB21D1), IFI16, STING (TMEM173), NFκB, and IRF3, which were readily detected in our 408 
mass spectrometry analysis (Table S1). RPTE cells are quite capable of responding to foreign 409 
intracellular DNA or RNA, leading to phosphorylation and nuclear translocation of IRF3, and 410 
RPTE cells also robustly express antiviral genes in response to type-1 interferon. However, we 411 
could not detect activation of these pathways even by three days after BKPyV infection: IRF3 412 
remains unphosphorylated and cytoplasmic and no ISGs were induced. Furthermore, we have also 413 
shown that active BKPyV infection within the same cell does not prevent the phosphorylation and 414 
nuclear translocation of IRF3 in response to either cytoplasmic RNA or DNA. This suggests that 415 
BKPyV is not actively suppressing such antiviral responses, but rather prevents its own detection 416 
by pathogen recognition receptors. This evasion of detection may be due to a combination of 417 
having a small circular double stranded DNA genome that is associated with histones, thus 418 
appearing similar to open chromatin, and tightly regulated entry and egress mechanisms to prevent 419 
exposure of viral DNA in the cytoplasm. Whether an inability to sense and respond to BKPyV 420 
infection is partly due to the nature of epithelial cells in the renourinary systems and whether this 421 
contributes to the natural tropism of BKPyV for these tissue types will be interesting questions for 422 
future study. 423 
In summary, we have generated extensive data sets on the protein expression profiles of primary 424 
epithelial cells of the kidney and bladder using advanced multiplexed proteomics and provided a 425 
detailed understanding of how infection by BKPyV modifies the protein expression profiles in 426 
these cells. This research has provided additional details of the specific cell cycle arrest induced by 427 
virus infection and revealed the importance of this arrest for BKPyV replication. Furthermore, our 428 
findings suggest a surprising ability of BKPyV to evade detection and activation of innate immune 429 
responses in cells that are natural sites of lytic virus infection in vivo. 430 
 431 
Materials and Methods 432 
Cell types, virus and primary antibodies. 433 
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HU cells were grown in Urothelial Cell Medium enriched with Urothelial Cell Growth 434 
Supplement and penicillin/streptomycin solution (Caltag Medsystems). HU cells were used at 435 
passage 4-6 for all experiments. RPTE cells were grown in renal epithelial basal media enriched 436 
with REGM bullet kit (Lonza). RPTE cells were used at passage 6-7 for all experiments. 437 
BKPyV (Dunlop strain) inserted into pGEM7Zf(+) vector (kindly provided by M. Imperiale, 438 
University of Michigan) was digested with BamHI, purified and re-ligated. Resultant BKPyV-439 
Dunlop genome was transfected into a T150 flask of RPTE cells, one week later the flask was split 440 
into three T150 flasks of RPTE cells. After a period of up to four weeks virus was harvested by 441 
freeze thawing cells three times. Virus purification by sucrose cushion, followed by caesium 442 
chloride gradient and dialysis provided purified BKPyV stocks as described previously (37). 443 
Concentration and purity was assessed by FFU assay and coomassie gel stain respectively. 444 
The primary antibodies used in this study were PAb597 against SV40 VP1 (kindly provided by W. 445 
Atwood, Brown University), P5G6 against BKPyV VP1 (kindly provided by D. Galloway, Fred 446 
Hutchinson Cancer Research Center), ab6160 against Tubulin (Abcam), ab32386 against Cyclin 447 
A2 (Abcam), ab32053 against Cyclin B1 (Abcam), MA5-11472 against CDK1 (Thermo 448 
Scientific), ab207604 against Cyclin D2, ab1101 against p53 (Abcam), GTX116125 against 449 
Geminin (GeneTex), ab16895 against MDM2 (Abcam), 37849 against MX1 (Cell Signalling 450 
Technologies), 2758 against ISG15 (Cell Signalling Technologies), PA3-848 against IFIT1 451 
(ThermoFisher), 12604-1-AP against IFIT2 (ProteinTech), SAB1410691 against IFIT3 (Sigma 452 
Aldrich), 11904 against IRF3 (Cell Signalling Technologies), ab76493 against IRF3 (phospho 453 
S386) (Abcam), ac-8023 against IFI16 (Santa Cruz), 11721 against BST2 (NIH AIDS Reagent 454 
Programme), ab53983 against SV40 VP2 + VP3 (Abcam), ab16879 against SV40 LTag (Abcam), 455 
and against BKPyV agnoprotein (rabbit polyclonal antibody generated against agnoprotein 456 
specific peptide). 457 
Cell infections and harvesting virus 458 
For viral infections RPTE or HU cells were infected with BKPyV at either MOI=5 for TMT and 459 
validation experiments, or MOI=3 or 0.5 for all other experiments, diluted in appropriate medium. 460 
At 1 hpi media was removed, cells washed twice with PBS and fresh medium was added. For 461 
TMT analysis, cells were harvested in TMT lysis buffer (6M Guanidine HCl, 50mM HEPES pH 462 
8.5), vortexed extensively and incubated at room temperature for 10 min. Lysates were then 463 
sonicated at 25 W for 30 s, followed by centrifugation at 21,000 g for 10 min, after which 464 
supernatant was transferred to a fresh tube. Centrifugation was repeated and supernatants snap-465 
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frozen in liquid nitrogen for further processing. For Western blot, cells were harvested by 466 
centrifugation at 6,000 g after two PBS washes. 467 
Transfection 468 
RPTE cells were transfected with pcDNA3-LTAg plasmid using TransIT-LT1 Transfection 469 
Reagent (Mirus) in Opti-MEM media according to the manufacturers protocol. 470 
Inhibitors 471 
For p53:MDM2 interaction inhibition experiments cells were treated at 2 hpi with Nutlin-3. 472 
Nutlin-3 (Sigma) was made up to 20mM in DMSO and used at 5µM. For cell cycle inhibition 473 
experiments cells were treated with inhibitors at 24 hpi. PD0332991 (Sigma) was made up to 5mM 474 
in dH2O and used at 1µM, Roscovitine (Sigma) was made up to 20mM in DMSO and used at 475 
20µM and RO-3306 (Sigma) was made up to 20mM in DMSO and used at 5µM. Controls were 476 
subjected to treatment with an equivalent amount of DMSO at the greatest volume of any inhibitor 477 
used. Cells were harvested in 1mL media at 48 hpi and either pelleted by centrifugation at 6,000 g 478 
for use in Western blot or qPCR, or frozen for assay by FFU. For analysis by flow cytometry cells 479 
were detached from wells by trypsin/EDTA treatment, centrifuged at 6,000 g, washed in PBS and 480 
fixed in 70% ice-cold ethanol. 481 
FFU and immunofluorescence microscopy 482 
Fluorescent focus unit (FFU) assays were used to determine the concentration of infectious virus 483 
in purified BKPyV stocks or experimental samples. RPTE cells were infected with sample 484 
dilutions, fixed at 48 hpi and immunostained for VP1 expression as described in (38). For 485 
comparison of inhibitor effects infectious BKPyV levels of uninhibited conditions were arbitrarily 486 
set to 1 and inhibited conditions corrected to this control for 7 independent experiments. A one 487 
sample t-test was conducted to give p values, standard deviation shown with error bars. 488 
For immunofluorescence analysis, RPTE cells were fixed in 3% formaldehyde. Fixed cells were 489 
then permeabilised and quenched (50mM NH4Cl and 0.1% Triton X-100 in PBS), blocked in 490 
PGAT (0.2% gelatin, 0.01% Triton X-100, 0.02% NaN3 in PBS) and stained with primary 491 
antibodies. Secondary antibodies used for immunofluorescence were Alexa Fluor 568 donkey anti-492 
mouse or goat anti-IgG1 mouse and Alexa Fluor 488 donkey anti-rabbit or goat anti-IgG2a mouse. 493 
Coverslips were mounted using SlowFade Gold with DAPI (Invitrogen). Samples were imaged 494 
using a 63x oil immersion lens on an Olympus IX81 wide-field fluorescent microscope. 495 
Western blot 496 
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RPTE cells were lysed by suspending in mRIPA (50mM Tris pH 7.5, 150mM NaCl, 1% Sodium 497 
Deoxycholate and 1% Triton X-100) supplemented with Complete Protease Inhibitors without 498 
EDTA (Roche). Cellular debris were removed by centrifugation at 17,000g. HU cells were lysed 499 
by suspending in HU cell Lysis Buffer (20mM HEPES pH 7.6, 250mM Sucrose, 2mM DTT, 2mM 500 
EDTA Na2 and 2mM EGTA) supplemented with Complete Protease Inhibitors without EDTA, 501 
followed by sonication at 25W for 30 sec. Proteins were separated by SDS-PAGE electrophoresis 502 
and transferred to nitrocellulose membranes before blocking in 5% skimmed milk powder in PBS.  503 
Following primary antibody binding, LI-COR IRDye680- (anti-mouse, anti-rabbit or anti-rat) or 504 
IRDye800-conjugated (anti-mouse or anti-rabbit) secondary antibodies were used. Membranes 505 
were then imaged on a LI-COR Odyssey Infrared Imaging system. 506 
Real-time PCR (qPCR) 507 
RPTE cell pellets were lysed in 200μL NDA Lysis Buffer (4M Guanidine Thiocyanate, 25mM 508 
Tris and 134mM β-mercaptoethanol) and incubated at 56°C for 10 min, after which an equal 509 
volume of 100% ethanol was added. DNA was then bound to silica columns by centrifuging at 510 
16,000× g for one min. Columns were washed with Buffer 1 (1M Guanidine Thiocyanate, 25mM 511 
Tris pH7 in 10% ethanol), and centrifuged, followed by a final wash in Buffer 2 (25mM Tris pH7 512 
in 70% ethanol). DNA was eluted with nuclease free water by centrifugation at 16,000× g. Primers 513 
and probe for BKPyV genome were designed as described in (38). Human TNFα primers and 514 
probe were designed and obtained through TIB MOLBIOL (forward primer: 515 
AGGAACAGCACAGGCCTTAGTG; reverse primer: AAGACCCCTCCCAGATAGATGG; 516 
Taqman probe: CCAGGATGTGGAGAGTGAACCGACATG). 300nM of each primer and 50nM 517 
of Taqman probe were used in each qPCR reaction, run on a Rotor-Gene (RG-3000, Corbett 518 
Research) and subsequently analysed on Rotor-Gene software. BKPyV genome levels were 519 
corrected to the TNFα control for each sample, and uninhibited samples arbitrarily set to 1, 6 520 
independent experiments. A one sample t-test was conducted to give p values, standard deviation 521 
shown with error bars. 522 
Flow cytometry 523 
Cellular DNA content was used as an indicator of cell cycle status. Cells were fixed in 70% 524 
ethanol for 30 mins, DNA was stained by resuspending each PBS washed cell pellet in 0.2mg 525 
RNAse A and 50μg propidium iodide in 1mL PBS and incubated at 37°C for 1 hr. Cells were then 526 
centrifuged at 6,000 g, supernatant removed and resuspended in 500μL PBS. Cells were analysed 527 
by flow cytometry using BD FACSCantoII with BD FACSDiva Software (BD Biosciences) and 528 
further analysed using FlowJo v10.4.2 cell cycle analysis function. A minimum of 10,000 cells 529 
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were collected for each sample, 3 independent experiments. Two-tailed students t-tests were 530 
conducted to assess significance of changes in cell cycle status between samples. Standard 531 
deviation error was calculated for each cell cycle status sample. 532 
Whole cell lysate protein digestion 533 
Cells were washed twice with PBS, and 250 µO lysis buffer added (6M Guanidine/50 mM HEPES 534 
pH 8.5). Cell lifters (Corning) were used to scrape cells in lysis buffer, which was removed to an 535 
eppendorf tube, vortexed extensively then sonicated. Cell debris was removed by centrifuging at 536 
21,000 g for 10 min twice. Dithiothreitol (DTT) was added to a final concentration of 5 mM and 537 
samples were incubated for 20 mins. Cysteines were alkylated with 14 mM iodoacetamide and 538 
incubated 20 min at room temperature in the dark. Excess iodoacetamide was quenched with DTT 539 
for 15 mins. Samples were diluted with 200 mM HEPES pH 8.5 to 1.5 M Guanidine followed by 540 
digestion at room temperature for 3 h with LysC protease at a 1:100 protease-to-protein ratio. 541 
Samples were further diluted with 200 mM HEPES pH 8.5 to 0.5 M Guanidine. Trypsin was then 542 
added at a 1:100 protease-to-protein ratio followed by overnight incubation at 37°C. The reaction 543 
was quenched with 5% formic acid, then centrifuged at 21,000 g for 10 min to remove undigested 544 
protein. Peptides were subjected to C18 solid-phase extraction (SPE, Sep-Pak, Waters) and 545 
vacuum-centrifuged to near-dryness. 546 
Peptide labelling with tandem mass tags 547 
In preparation for TMT labelling, desalted peptides were dissolved in 200 mM HEPES pH 8.5. 548 
Peptide concentration was measured by microBCA (Pierce), and 25μg labelled with TMT reagent. 549 
TMT reagents (0.8 mg) were dissolved in 43 μl anhydrous acetonitrile and 3 μl added to peptide at 550 
a final acetonitrile concentration of 30% (v/v). Samples were labelled as follows. Experiment 1 (9-551 
plex); 126 – mock infection 12 hpi, 127N – mock infection 24 hpi, 127C – mock infection 48 hpi, 552 
128N – BKPyV infection 12 hpi, 128C – BKPyV infection 24 hpi, 129N – BKPyV irradiated – 48 553 
hpi, 129C – BKPyV irradiated 24 hpi, 130N BKPyV infection 48 hpi. Experiment 2 (10-plex); 126 554 
– HU cells mock infection 24 hpi, 127N – HU cells mock infection 72 hpi, 127C – HU cells 555 
BKPyV infection 24 hpi, 128N – HU cells BKPyV infection 48 hpi, 128C – HU cells BKPyV 556 
infection 72 hpi, 129N – RPTE cells mock infection 24 hpi, 129C – RPTE cells mock infection 72 557 
hpi, 130N – RPTE cells BKPyV infection 24 hpi, 130C – RPTE cells BKPyV infection 48 hpi, 558 
131N – RPTE cells BKPyV infection 72 hpi. Following incubation at room temperature for 1 h, 559 
the reaction was quenched with hydroxylamine to a final concentration of 0.3% (v/v). TMT-560 
labelled samples were combined at a 1:1:1:1:1:1:1:1:1 ratio (experiment 1) and 1:1:1:1:1:1:1:1:1:1 561 
ratio (experiment 2). The sample was vacuum-centrifuged to near dryness and subjected to C18 562 
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SPE (Sep-Pak, Waters). An unfractionated singleshot was initially analysed to ensure similar 563 
peptide loading across each TMT channel, to avoid the need for excessive electronic 564 
normalization. Quantities of each TMT labelled sample were adjusted prior to high pH reversed-565 
phase (HpRP) so that normalisation factors were >0.67 and <1.5. Normalisation is discussed in 566 
‘Data Analysis’, and fractionation is discussed below. 567 
Offline HpRP fractionation 568 
TMT-labelled tryptic peptides were subjected to HpRP fractionation using an Ultimate 3000 569 
RSLC UHPLC system (Thermo Fisher Scientific) equipped with a 2.1 mm internal diameter (ID) 570 
x 25 cm long, 1.7 µm particle Kinetix Evo C18 column (Phenomenex). Mobile phase consisted of 571 
A: 3% acetonitrile (MeCN), B: MeCN and C: 200 mM ammonium formate pH 10. Isocratic 572 
conditions were 90% A / 10% C, and C was maintained at 10% throughout the gradient elution. 573 
Separations were conducted at 45°C. Samples were loaded at 200 µl/minute for 5 minutes. The 574 
flow rate was then increased to 400 µl/minute over 5 minutes, after which the gradient elution 575 
proceed as follows: 0-19% B over 10 minutes, 19-34% B over 14.25 minutes, 34-50% B over 8.75 576 
minutes, followed by a 10 minutes wash at 90% B. UV absorbance was monitored at 280 nm and 577 
15 s fractions were collected into 96 well microplates using the integrated fraction collector. 578 
Fractions were recombined orthogonally in a checkerboard fashion, combining alternate wells 579 
from each column of the plate into a single fraction, and commencing combination of adjacent 580 
fractions in alternating rows. Wells prior to the start or after the stop of elution of peptide-rich 581 
fractions, as identified from the UV trace, were excluded. This yielded two sets of 12 combined 582 
fractions, A and B, which were dried in a vacuum centrifuge and resuspended in 10 µl MS solvent 583 
(4% MeCN / 5% formic acid) prior to LC-MS3. 11 set ‘A’ fractions were used for experiment 1 584 
and 10 set ‘A’ fractions were used for experiment 2. 585 
LC-MS3 586 
Mass spectrometry data was acquired using an Orbitrap Lumos (Thermo Fisher Scientific, San 587 
Jose, CA). An Ultimate 3000 RSLC nano UHPLC equipped with a 300 µm ID x 5 mm Acclaim 588 
PepMap µ-Precolumn (Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 µm particle 589 
Acclaim PepMap RSLC analytical column was used. 590 
Loading solvent was 0.1% formic acid (FA), analytical solvent A: 0.1% FA and B: 80% MeCN + 591 
0.1% FA. All separations were carried out at 55°C. Samples were loaded at 5 µL/minute for 5 592 
minutes in loading solvent before beginning the analytical gradient. The following gradient was 593 
used: 3-7% B over 3 minutes, 7-37% B over 173 minutes, followed by a 4 minute wash at 95% B 594 
and equilibration at 3% B for 15 minutes. Each analysis used a MultiNotch MS3-based TMT 595 
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method (39, 40). The following settings were used Th, 120,000 Resolution, 2x105 automatic gain 596 
control (AGC) target, 50 ms maximum injection time. MS2: Quadrupole isolation at an isolation 597 
width of m/z 0.7, CID fragmentation (normalised collision energy (NCE) 35) with ion trap 598 
scanning in turbo mode from m/z 120, 1.5x104 AGC target, 120 ms maximum injection time. 599 
MS3: In Synchronous Precursor Selection mode the top 6 MS2 ions were selected for HCD 600 
fragmentation (NCE 65) and scanned in the Orbitrap at 60,000 resolution with an AGC target of 601 
1x105 and a maximum accumulation time of 150 ms. Ions were not accumulated for all 602 
parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. Dynamic exclusion was 603 
set to +/- 10 ppm for 70 s. MS2 fragmentation was trigged on precursors 5x103 counts and above. 604 
Data analysis 605 
In the following description, we list the first report in the literature for each relevant algorithm. 606 
Mass spectra were processed using a Sequest-based software pipeline for quantitative proteomics, 607 
“MassPike”, through a collaborative arrangement with Professor Steve Gygi’s laboratory at 608 
Harvard Medical School. MS spectra were converted to mzXML using an extractor built upon 609 
Thermo Fisher’s RAW File Reader library (version 4.0.26). In this extractor, the standard mzxml 610 
format has been augmented with additional custom fields that are specific to ion trap and Orbitrap 611 
mass spectrometry and essential for TMT quantitation. These additional fields include ion 612 
injection times for each scan, Fourier Transform-derived baseline and noise values calculated for 613 
every Orbitrap scan, isolation widths for each scan type, scan event numbers, and elapsed scan 614 
times. This software is a component of the MassPike software platform and is licensed by Harvard 615 
Medical School. 616 
A combined database was constructed from (a) the human Uniprot database (4th February 2014), 617 
(b) the BK polyomavirus database (6th October, 2014). The combined database was concatenated 618 
with a reverse database composed of all protein sequences in reversed order. Searches were 619 
performed using a 20 ppm precursor ion tolerance (41). Product ion tolerance was set to 0.03 Th. 620 
TMT tags on lysine residues and peptide N termini (229.162932 Da) and carbamidomethylation of 621 
cysteine residues (57.02146 Da) were set as static modifications, while oxidation of methionine 622 
residues (15.99492 Da) was set as a variable modification. 623 
To control the fraction of erroneous protein identifications, a target-decoy strategy was employed 624 
(42, 43). Peptide spectral matches (PSMs) were filtered to an initial peptide-level false discovery 625 
rate (FDR) of 1% with subsequent filtering to attain a final protein-level FDR of 1% (44, 45). PSM 626 
filtering was performed using a linear discriminant analysis, as described previously (46). This 627 
distinguishes correct from incorrect peptide IDs in a manner analogous to the widely used 628 
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Percolator algorithm (47), though employing a distinct machine learning algorithm. The following 629 
parameters were considered: XCorr, ΔCn, missed cleavages, peptide length, charge state, and 630 
precursor mass accuracy. Protein assembly was guided by principles of parsimony to produce the 631 
smallest set of proteins necessary to account for all observed peptides (46). 632 
Proteins were quantified by summing TMT reporter ion counts across all matching peptide-633 
spectral matches using ”MassPike”, as described previously (39, 40). Briefly, a 0.003 Th window 634 
around the theoretical m/z of each reporter ion (126, 127n, 127c, 128n, 128c, 129n, 129c, 130n, 635 
130c, 131n, 131c) was scanned for ions, and the maximum intensity nearest to the theoretical m/z 636 
was used. The primary determinant of quantitation quality is the number of TMT reporter ions 637 
detected in each MS3 spectrum, which is directly proportional to the signal-to-noise (S:N) ratio 638 
observed for each ion (48). Conservatively, every individual peptide used for quantitation was 639 
required to contribute sufficient TMT reporter ions (minimum of ~1250 per spectrum) so that each 640 
on its own could be expected to provide a representative picture of relative protein abundance (39). 641 
An isolation specificity filter was additionally employed to minimise peptide co-isolation (49). 642 
Peptide-spectral matches with poor quality MS3 spectra (more than 9 TMT channels missing 643 
and/or a combined S:N ratio of less than 250 across all TMT reporter ions) or no MS3 spectra at 644 
all were excluded from quantitation. Peptides meeting the stated criteria for reliable quantitation 645 
were then summed by parent protein, in effect weighting the contributions of individual peptides 646 
to the total protein signal based on their individual TMT reporter ion yields. Protein quantitation 647 
values were exported for further analysis in Excel. 648 
For protein quantitation, reverse and contaminant proteins were removed, then each reporter ion 649 
channel was summed across all quantified proteins and normalised assuming equal protein loading 650 
across all channels. For further analysis and display in figures, fractional TMT signals were used 651 
(i.e. reporting the fraction of maximal signal observed for each protein in each TMT channel, 652 
rather than the absolute normalized signal intensity). This effectively corrected for differences in 653 
the numbers of peptides observed per protein. For all TMT experiments, normalised S:N values 654 
are presented in Table S1 (‘Data’ worksheet). 655 
Hierarchical centroid clustering based on uncentered Pearson correlation, and k-means clustering 656 
were performed using Cluster 3.0 (Stanford University) and visualised using Java Treeview 657 
(http://jtreeview.sourceforge.net) unless otherwise noted. 658 
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Figure Legends 805 
Figure 1. Quantitative temporal analysis of BK virus lytic infection. 806 
 24 
(A) Schematic of experimental workflow. RPTE and HU cells were infected at MOI 5 or mock 807 
infected. Whole cell lysates (WCL) were harvested at 24, 48, and 72 h (infected samples) 808 
or 24 and 72 h (mock infected samples). 809 
(B) Hierarchical cluster analysis of all quantified proteins. 810 
(C) Scatter plots of all proteins quantified at 24, 48 and 72 hpi in RPTE and HU cells. Fold 811 
change is shown in comparison to the average corresponding mock for the same cell type. 812 
Benjamini-Hochberg-corrected significance B was used to estimate p-values (50). 813 
(D) Scatter plot showing the correlation between protein abundance changes in BKPyV 814 
infected RPTE and HU cells, and overlap of proteins up and downregulated by > 2-fold 815 
between RPTE and HU cells. 816 
(E) Temporal profiles of the 5 viral proteins identified, normalised to a maximum of one. 817 
 818 
Figure 2. Repeat quantitative temporal profiling in RPTE cells (Experiment 2). 819 
(A) Schematic of experimental workflow for experiment 2. 820 
(B) Scatter plots of all proteins quantified. Fold change is shown in comparison to the average 821 
corresponding mock. Benjamini-Hochberg-corrected significance B was used to estimate 822 
p-values (Cox and Mann, 2008). 823 
(C) Overlap of proteins quantified between Experiment 1 and Experiment 2. 824 
(D) Scatter plot showing the correlation between experiments 1 and 2 in RPTE cells, for 825 
proteins quantified by ≥2-peptides. 826 
(E) Temporal profiles of the 5 viral proteins quantified, normalised to a max of one. 827 
 828 
Figure 3. Proteins involved in the innate antiviral immune response remain unchanged 829 
during BKPyV infection. 830 
(A) Up- or down-regulation of a minority of proteins with innate antiviral function (Uniprot 831 
keywords: ‘Innate immunity’ and ‘Antiviral’). 832 
(B) Example protein profiles from (A). 833 
(C) Validation of temporal profiles shown in (B) by Western blot. RPTE cells were mock 834 
infected or infected with BKPyV at MOI 3 or stimulated with IFNα2A (104 U/mL) and 835 
analysed by Western blot for the proteins shown.  836 
 837 
Figure 4. RPTE cells phosphorylate and translocate IRF3 in response to cytoplasmic RNA 838 
and DNA but fail to do so upon BKPyV infection. 839 
(A) Immunofluorescence microscopy analysis of IRF3 localisation changes upon stimulation. 840 
RPTE cells infected with BKPyV (MOI 0.5) or mock infected were fixed at 48 hpi. RPTE 841 
cells stimulated with Poly I:C (2 µg/mL) or stimulatory DNA (2 µg/mL) were fixed at 6 h 842 
after stimulation. DAPI was used as a nuclear marker and anti-VP1 as a marker of 843 
infection. 844 
(B) Analysis of IRF3 phosphorylation by Western blot. RPTE cells infected with BKPyV 845 
(MOI 3) or mock infected and harvested at 48 hpi. RPTE cells stimulated with Poly I:C (2 846 
µg/mL) or stimulatory DNA (2 µg/mL) were harvested at 6 h after stimulation.  847 
 848 
Figure 5. BKPyV and mock-infected RPTE cells do not differ in their responses to 849 
cytoplasmic RNA and DNA. 850 
(A) Immunofluorescence microscopy analysis of IRF3 localisation changes upon stimulation in 851 
BKPyV infected or uninfected cells. RPTE cells infected with BKPyV (MOI 0.5) or mock 852 
infected were stimulated with Poly I:C (2 µg/mL) or oligomeric DNA (2 µg/mL) at 42 hpi 853 
and fixed at 48 hpi. DAPI was used as a nuclear marker and anti-LTAg as a marker of 854 
infection. 855 
(B) Analysis of IRF3 phosphorylation upon stimulation in BKPyV infected or uninfected cells 856 
by Western blot. RPTE cells infected with BKPyV (MOI 3) or mock infected were 857 
 25 
stimulated with Poly I:C (2 µg/mL) or oligomeric DNA (2 µg/mL) at 42 hpi and fixed at 48 858 
hpi. 859 
 860 
Figure 6. Upregulated proteins are enriched in cell cycle functions. 861 
(A) DAVID enrichment analysis of proteins upregulated or downregulated >2-fold against a 862 
background of all 8985 human proteins quantified in Experiment 1. No significantly 863 
enriched downregulated clusters were observed for HU cells. 864 
(B) Example protein profiles for selected cell cycle-related proteins for both RPTE and HU 865 
cells. Proteins families are separated by coloured boxes. 866 
(C) Validation of selected temporal profiles shown in (B) by Western blot (RPTE cells, MOI 867 
3). Tubulin was used as a loading control and VP1 as a control for infection. 868 
 869 
Figure 7. MDM2 and p53 are modulated by BKPyV via LTAg-dependent and -independent 870 
activities. 871 
(A) Expression of MDM2, p53 and LTAg in RPTE cells infected with BKPyV (MOI 1) or 872 
mock infected, then treated with 5 µM Nutlin-3 or DMSO as a control at 2 hpi, fixed at 48 873 
hpi. DAPI was used as a nuclear marker.  874 
(B) Expression of MDM2, p53 and LTAg in RPTE cells transfected with BKPyV LTAg, then 875 
treated with 5 µM Nutlin-3 or DMSO as a control at 2 h and subjected to cell cycle 876 
inhibition (RO-3306 5 µM) at 24 h, fixed at 48 h post transfection. DAPI was used as a 877 
nuclear marker. Five example cells shown for each condition 878 
 879 
Figure 8. Cell cycle inhibitors have variable effects on BKPyV induced G2/M phase cell cycle 880 
arrest. 881 
(A) The cell cycle status of RPTE cells was determined in a number of different experimental 882 
conditions. RPTE cells were infected with BKPyV (MOI 3) or mock infected, then 883 
subjected to CDK4/6 inhibition (PD0332991 1 µM), CDK1/2 inhibition (Roscovitine 20 884 
µM) or CDK1 inhibition (RO-3306 5 µM) at 24 hpi, and subsequently collected for 885 
analysis at 48 hpi. Collected cells were stained with propidium iodide (PI) and analysed by 886 
flow cytometry (n=3). Error bars represent standard deviation. *p < 0.05; **p < 0.01; ***p 887 
< 0.001; ns = not significant; two sample t-test for changes in proportion of cells in G1.  888 
(B) Histograms of PI stain for each experimental condition of a single experiment shown. 889 
(C) Cell viability tests. RPTE cells were treated with 1 µM PD0332991, 20 µM Roscovitine or 890 
5 µM RO-3306 for 24 h then subjected to a Trypan Blue exclusion assay according to 891 
manufacturers protocol (n=3). 892 
 893 
Figure 9. CDK1 and 2 inhibitors impede BKPyV replication in RPTE cells.  894 
RPTE cells infected with BKPyV (MOI=3) were subjected to CDK4/6 inhibition (1 µM 895 
PD0332991), CDK1/2 inhibition (20 µM Roscovitine) or CDK1 inhibition (5 µM RO-896 
3306) from 24 hpi and harvested for analysis at 48 hpi. 897 
(A) qPCR to determine viral DNA copy numbers per cell. DNA was extracted from each 898 
condition, BKPyV genome copy number was determined, normalised to host gene (TNFα) 899 
copy number and compared to the uninhibited control, which was arbitrarily set to 1 (n=6). 900 
(B) Expression of viral proteins VP1, VP2, VP3, Agno, and LTAg was determined by Western 901 
blot. Tubulin was used as a loading control. 902 
(C) Infectious BKPyV produced in each experimental condition was determined by fluorescent 903 
focus unit (FFU) assay and normalised to uninhibited control (arbitrarily set to 1) (n=7).   904 
Error bars represent standard deviation. *p < 0.05; ***p < 0.001; ****p < 0.0001; ns = not 905 
significant; one sample t-test experimental conditions versus control.  906 
 907 
Figure 10. Proposed mechanism of interplay between MDM2 and p53 levels in the presence 908 
of LTAg  909 
 26 
(A) Untreated cells. 910 
(B) Uninfected, untransfected cells inhibited with Nutlin-3. 911 
(C) Cells expressing LTAg in the absence of infection. 912 
(D) Cells BKPyV infected, or cells expressing LTAg combined with cell cycle arrest/DNA 913 
damage. 914 
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